ArcellxACLX
ACLX
About: Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Employees: 163
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
104% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 25
35% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 55
20% more funds holding in top 10
Funds holding in top 10: 10 [Q3] → 12 (+2) [Q4]
17.34% more ownership
Funds ownership: 92.06% [Q3] → 109.39% (+17.34%) [Q4]
12% more funds holding
Funds holding: 186 [Q3] → 209 (+23) [Q4]
10% more capital invested
Capital invested by funds: $4.13B [Q3] → $4.54B (+$402M) [Q4]
8% more call options, than puts
Call options by funds: $35.8M | Put options by funds: $33.3M
Research analyst outlook
We haven’t received any recent analyst ratings for ACLX.
Financial journalist opinion
Neutral
Business Wire
1 month ago
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare.
Neutral
GlobeNewsWire
1 month ago
Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Arcellx, Inc. (NASDAQ: ACLX) Chief Medical Officer Christopher Heery, M.D., and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University.
Positive
Seeking Alpha
1 month ago
Arcellx Impressive Safety Data Leaves Doubts
Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet medical need. Strong clinical trial results and strategic partnerships bolster confidence in Arcellx's growth trajectory and market position. Clarity is needed around mechanistic differentiation on D-Domain safety results before fully buying into the story.
Negative
Zacks Investment Research
1 month ago
Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to earnings of $0.42 per share a year ago.
Neutral
Business Wire
1 month ago
Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2024. “2024 was a transformational year for Arcellx as our ASH data presentations for anito-cel, in partnership with Kite, continued to demonstrate anito-cel's diff.
Neutral
Business Wire
1 month ago
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors s.
Positive
Zacks Investment Research
3 months ago
5 Biotech Breakthrough Stocks to Watch in 2025
After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services.
Positive
Investors Business Daily
4 months ago
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti. The post Arcellx And Legend Bio Trade Jabs In Multiple Myeloma.
Positive
Benzinga
4 months ago
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
On Sunday, Arcellx, Inc. ACLX revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM).
Neutral
Business Wire
4 months ago
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the 66th American Society of.
Charts implemented using Lightweight Charts™